Skip to content

Clinical diagnostic test of biomarkers in pleural effusion

Diagnostic Performance of interleukin for Tuberculous Pleural Effusion

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100051112
Enrollment
Unknown
Registered
2021-09-14
Start date
2018-01-01
Completion date
Unknown
Last updated
2022-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pleural disease

Interventions

Gold Standard:TPE was diagnosed if one of the following criteria was met: caseous granuloma observed in pleural biopsy, acid-fast staining positive or Mtb culture-positive in PE, and clinical data wer
Index test:Interleukin,Adenosine&#32
deaminase

Sponsors

Beijing Chao-Yang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: TPE was diagnosed if one of the following criteria was met: caseous granuloma observed in pleural biopsy, acid-fast staining positive or Mtb culture-positive in PE, and clinical data were highly suspected of tuberculosis with an improvement of the effusion after and the anti-tuberculous therapy. Malignant pleural effusion (MPE) was considered if malignant cells were observed in the PE or pleural biopsy specimens. Parapneumonic pleural effusion (PPE) was classified as PE associated with bacterial pneumonia, lung abscess, or bronchiectasis. Miscellaneous pleural effusion referred to PE caused by other diseases.

Exclusion criteria

Exclusion criteria: Exclusion criteria were as follows: patients who received anti-tuberculous or antitumor therapy before admission, those with immunosuppressive status (diabetes, HIV, hepatitis B/C, hormonal, or immunosuppressive therapy), those with intrathoracic invasive procedures or chest trauma within 3 months, those with undetermined diagnosis, or those with empyema and transudate effusion.

Design outcomes

Primary

MeasureTime frame
Interleukin;

Secondary

MeasureTime frame
Adenosine deaminase;

Countries

China

Contacts

Public ContactShi Huanzhong

Beijing Chao-Yang Hospital

shihuanzhong@ccmu.edu.cn+86 10 85231412

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026